Hørsholm, Denmark, and Oxford, UK, October 15, 2012 / B3C newswire / – Biotech company ExpreS2ion Biotechnologies today announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion’s Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production. The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford. The platform will be used by various research teams to address expression of complex and “difficult-to-make” proteins.
This license is a perfect example of ExpreS2ion Biotechnologies’ vision of making its production platform available to academic centers of excellence globally, in complement to the Company’s strategy of making S2 one of the standard protein production platforms in the vaccine and therapeutic protein segments.
Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: “We are delighted that the Jenner Institute at Oxford University has taken a Research License to our proprietary ExpreS2 platform for protein expression. The ExpreS2 platform has shown to provide a way forward to projects with a need for a robust and fully scalable protein production platform, such as certain challenging recombinant subunit vaccine projects.
ExpreS2ion is proud to enter this Agreement with the University of Oxford, one of the world’s most prestigious Universities, with well-established, world-recognized medical research.”
Dr. Simon Draper, a MRC Research Fellow, commented: “access to the ExpreS2 platform at the Jenner Institute in Oxford will greatly expand our protein vaccine production capabilities. We are looking forward to working with ExpreS2ion Biotechnologies as we develop new clinically-relevant protein vaccines to target difficult pathogens, such as malaria.”
ExpreS2ion Biotechnologies has developed a complete proprietary protein expression platform, ExpreS2, based on engineered Drosophila Schneider-2 (S2) cells to serve recombinant protein production needs in the biopharmaceutical industry as well as in academia. ExpreS2 allows quick access to proteins, excellent protein expression capability, scalability, applicability to high cell density production processes and regulatory friendliness.
ExpreS2ion Biotechnologies offers technology platform licensing opportunities for use in R&D and commercial protein manufacturing.
About The Jenner Institute
The Jenner Institute is a research partnership between the University of Oxford and the Pirbright Institute (formerly Institute for Animal Health). The Institute focuses on the parallel development of human and veterinary vaccines against major global diseases – from early-stage research through to clinical trials. For more information on the Oxford vaccine programmes visit: www.jenner.ac.uk.
About Oxford University
Oxford University’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu.
Sancha Salgueiro, Ph.D., MBA
Vice President Business Development
Agern Allé 1, DK-2970 Hørsholm, Denmark
Phone: (+45) 41 666 121